Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Jaypirca® (pirtobrutinib), a non-covalent ...

Patients with relapsed or refractory chronic lymphocytic leukemia (r/r CLL) saw benefits from treatment with fixed-duration Jaypirca (pirtobrutinib) plus Venclexta (venetoclax; PV) and Jaypirca plus ...

recently-approved Jaypirca (pirtobrutinib) for mantle cell lymphoma, and lebrikizumab for atopic dermatitis, which was also rejected by the FDA in a decision earlier this month. Lilly abandoned ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

Analyst Sel Hardy is bullish on several late-stage Eli Lilly drugs, particularly pirtobrutinib for certain forms of leukemia and lymphoma and tirzepatide for sleep apnea and cardiology.

Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Jaypirca® (pirtobrutinib), a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, will be presented at ...

A comparison of the second-generation Bruton tyrosine kinase (BTK) inhibitor acalabrutinib to the first-generation ibrutinib shows the former had lower rates of adverse events in a real-world ...

Expert Rev Hematol. 2013;6(4):441-449. In conclusion, although age should generally determine the goal of treatment in CLL, the patient's functional status rather than chronological age can be ...

Antibiotic therapy with moxifloxacin in this large-scale PMS study resulted in rapid improvement in symptoms of acute sinusitis. Moxifloxacin was remarkably well tolerated in the examined patient ...

INDIANAPOLIS, Oct. 30, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its financial results for the third quarter of 2024. "Lilly had another strong growth quarter in Q3 ...

INDIANAPOLIS, Nov. 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Jaypirca® (pirtobrutinib), a non-covalent (reversible) Bruton's tyrosine ...

Analyst Sel Hardy says Eli Lilly has several bullish catalysts ahead in 2024 and beyond, including Alzheimer's disease drug donanemab, cancer drug pirtobrutinib and sleep apnea and cardiology drug ...